PDB14 USING HEALTH OUTCOMES MODELING TO ASSESS THE BENEFIT-RISK PROFILE OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE-2 DIABETES
Abstract
Authors
L. Garrison J.H. Best J.C. Robertson M. Wenten D. Bruhn
L. Garrison J.H. Best J.C. Robertson M. Wenten D. Bruhn
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now